CDKN2A Recombinant Monoclonal Antibody

Code: CSB-RA084523A0HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, IHC, IF, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P42771

Target Names

CDKN2A

Alternative Names

CDKN2A antibody; CDKN2 antibody; MTS1 antibody; Cyclin-dependent kinase inhibitor 2A antibody; Cyclin-dependent kinase 4 inhibitor A antibody; CDK4I antibody; Multiple tumor suppressor 1 antibody; MTS-1 antibody; p16-INK4a antibody; p16-INK4 antibody; p16INK4A antibody

Species Reactivity

Human

Immunogen

A synthesized peptide derived from human CDKN2A

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

5A1

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Immunohistochemistry (IHC) Protocol Immunofluorescence (IF) Protocol Flow Cytometry (FC) Protocol

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200
IF	1:50-1:200
FC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

IHC image of CSB-RA084523A0HU diluted at 1:100 and staining in paraffin-embedded human testis tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.
Immunofluorescence staining of Hela cell with CSB-RA084523A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
Overlay Peak curve showing Hela cells stained with CSB-RA084523A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

CDKN2A, also known as p16-INK4a, serves as a critical tumor suppressor that regulates cell cycle progression by inhibiting cyclin-dependent kinase 4. This protein plays a fundamental role in cellular senescence and acts as a key barrier against oncogenic transformation. Loss or inactivation of CDKN2A is among the most frequent alterations observed in human cancers, making it an essential marker for cancer research, cell cycle studies, and investigations into aging mechanisms.

This recombinant monoclonal antibody offers researchers the reproducibility advantages inherent to recombinant technology. Because the antibody sequence is defined and produced from a stable expression system, you can expect consistent performance across experiments and over time, eliminating the lot-to-lot variability that can complicate long-term studies or multi-site collaborations. The antibody is raised in rabbit against a synthetic peptide derived from human CDKN2A and purified by affinity chromatography to ensure high specificity.

Validation data demonstrates reliable performance across multiple experimental platforms. Immunohistochemistry staining in paraffin-embedded human testis tissue shows clear detection using a standard citrate buffer antigen retrieval protocol at dilutions between 1:50 and 1:200. Immunofluorescence analysis in HeLa cells reveals distinct nuclear and cytoplasmic localization patterns, while flow cytometry experiments with the same cell line confirm robust signal separation from isotype controls, supporting quantitative single-cell analyses.

This versatility across tissue sections, cultured cells, and flow cytometry workflows makes the antibody well-suited for researchers investigating CDKN2A expression in tumor biology, senescence pathways, or cell cycle regulation. The unconjugated format provides flexibility for pairing with your preferred secondary detection systems.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.

Gene References into Functions

Increased expression of epithelial and stromal p16(CDKN2A) in all grades of cervical intraepithelial neoplasia and cancer PMID:30059872
Data indicate a cell regulatory mechanism through which lysine-specific demethylase 2B (KDM2B) promotes triple negative breast cancer (TNBC) cell proliferation by binding to the promoters of cell cycle inhibitors p15INK4B, p16INK4A, and p57KIP2. PMID:30060056
results suggest that lower P16(INK4A) expression associated with highercancer stem cells (CSCs) markers predicts poor prognostic outcomes and is a promising target in patients with cervical cancer. PMID:30150594
In this review, we discuss recent findings on the regulation of p16-INK4a by covalent modifications at both transcriptional and post-translational levels. PMID:30482142
Knockdown of cyclin dependent kinase inhibitor 2A (p16INK4A) in cardiac stem/progenitor cell (hCPC) reverses the senescent phenotype and has an antioxidant effect on aging hCPCs via NF-KAPPA B (NF-kB) signaling. PMID:29675777
CDKN2A methylation is involved in the carcinogenesis, progression, and metastasis of head and neck squamous cell carcinoma; could be a potential diagnostic and prognostic biomarker (Meta-Analysis) PMID:30355925
CDKN2A overexpression was cell-type dependent in adenoid cystic carcinoma in the lacrimal gland, while HPV infection was negative. PMID:29430168
Study reveals the novel function of NOX4 in reprogramming aerobic glycolysis initiated by activated Kras and inactivated p16 in pancreatic ductal adenocarcinoma. PMID:28232723
we were able to document the loss of p16 protein expression and CDKN2A gene aberrancy in a subset of conventional and fibrosarcomatous dermatofibrosarcoma protuberans cases PMID:29743142
ARF is a tumor suppressor protein that has a pivotal role in the prevention of cancer development through regulating cell proliferation, senescence, and apoptosis. As a factor that induces senescence, the role of ARF as a tumor suppressor is closely linked to the p53-MDM2 axis, which is a key process that restrains tumor formation. Review. PMID:29665672
p16/Ki-67 dual immunostaining had comparable sensitivity and improved specificity in screening high-grade cervical intraepithelial neoplasm (HGCIN) or CC when compared with hrHPV detection. Further studies may be beneficial to assess the efficacy of this novel biomarker, which can be potentially used as one of the initial screening assays. PMID:30249873
Findings outlined in the current study demonstrated that the inhibition of P16 decreased the growth and metastasis potential of BC cells by inhibiting IL-6/JAK2/STAT3 signaling. PMID:29388151
Loss of P14ARF expression is associated with small intestinal adenocarcinoma. PMID:30375264
These results...suggest that nucleolar p14ARF can be used as early prognostic marker in chronic liver disease to reliably identify patients with high risk for developing liver cancer PMID:29228217
a antagonizing mechanism coordinating Arg 138 methylation and Ser 140 phosphorylation to regulates p16 function as well as cellular apoptosis and senescence. PMID:28120917
The aim of this study was to investigate the expression of p16 and SATB1 proteins in regard to expression of the Ki-67 antigen and available clinicopathological data (i.a. receptor status, staging and grading PMID:29936452
rognostic impact of p16 can be emphasized in a subgroup of oropharyngeal squamous cell carcinoma (OSCC) patients undergoing surgery. Surgery with sufficient surgical margin may be chosen as the first treatment for HPV-negative OSCC in some cases PMID:29936482
Low P16INK4A expression is associated with laryngeal squamous cell carcinomas. PMID:30275203
These results confirm that CDKN2A is a tumor suppressor gene driving human cancer development by inducing cell aneuploidy and cell cycle up-regulation PMID:30136875
This study demonstrated that p16/Ki-67 dual staining represents an effective method for cervical cancer screening. Application of this method could lead to a reduction of unnecessary colposcopy referrals and misdiagnosis. PMID:29758205
Non-significant association was seen in the two single nucleotide polymorphisms (SNPs) of CDKAL1 (rs7754840) and CDKN2A/2B (rs10811661) with gestational diabetes mellitus (GDM). PMID:29544538
In conclusion, this meta-analysis showed that decreased p16(INK4a) expression is associated with lower overall survival rate in patients with STS, and it is an effective biomarker of prognosis. PMID:29798963
CDKN2A mutation carriers presented more atypical naevi, multiple melanomas, and basal cell carcinoma. PMID:29405243
hsa_circ_0014717 acts as a potential tumor suppressor that inhibits colorectal cancer growth, partly at least, through upregulating p16 expression. PMID:29571246
Anti-E2, -L1, and -p16(INK4A) antibodies in sera were determined by western blot. Among 116 samples, 69 (60%) were HPV DNA-positive. Percentages seropositive for anti-E2, -L1, and -p16(INK4A) antibodies were 39.6, 22.4, and 23.3%, respectively. PMID:29744680
p16 represents a useful supplementary marker for diagnosis of SCLC, even in cases where only cytological material is available PMID:29566943
this study shows that basaloid squamous cell carcinoma and basal cell carcinoma of the head and neck can be readily distinguished by a limited panel consisting primarily of EMA, and supported by SOX2 and p16 PMID:27438511
p16 IHC is an independent prognostic biomarker in pleural mesothelioma PMID:28889523
It plays a role for small intestine-specific gene regulation and alterations of the CDKN2A/CDKN2B locus could affect the pathophysiology of inflammatory bowel disease. PMID:29063720
p16/Ki-67 dual staining can increase the efficiency of screening methods for cervical cancer. PMID:29895125
The methylation of the p16 gene promoter could significantly reduce p16 expression, losing its tumor suppressor activity and promoting the development of cervical cancer. PMID:28617556
Co-administration of VOR did not increase the overall response rate (P = 0.84) or overall survival (OS; P = 0.32). Specifically, no benefit was identified in either de novo or relapsed AML. Mutations in the genes CDKN2A (P = 0.0001), IDH1 (P = 0.004), and TP53 (P = 0.003) were associated with reduced OS PMID:28765326
The increased expression of p16ink4a may affect the activity of Wnt/betacatenin signaling through modulation of the expression of betacatenin. PMID:29207089
Alterations in chromatin-remodeling genes and CDKN2A contribute to metastasis of pancreatic neuroendocrine tumors. PMID:29486199
data suggest that a P16-dependent pathway drives the induction of cellular senescence in dental follicle cells. PMID:28770470
rs2518719 is a pleiotropic CDKN2A variant associated with the risk of developing pancreatic neuroendocrine tumors PMID:28008994
Hypermethylation of p14 appears to be an important event in the development of mucoepidermoid carcinoma. High frequency of gene hypermethylation and high incidence of methylation at multiple sites point to the importance of epigenetic phenomena in the pathogenesis of MECs, although with modest impact on clinical parameters. PMID:29079368
perinatal methylation at CDKN2A is associated with childhood bone development. PMID:28419547
Final follow-up showed 45 cases of spontaneous lesion regression and 42 cases of persistence with absence of protein p164NK4a in all of them PMID:29787011
CDKN2A/p16 frequently alters in oral cancer progression with a deletion/loss of function in the recurrent cases displaying its role in aiding several molecular events for the malignant transformations occurring throughout disease progression PMID:28939073
Data suggest that stromal cyclin-dependent kinase inhibitor p16 (p16) expression is involved in the development and progression of gastric-type mucinous carcinoma (MC-G). PMID:29848709
Report p16 immunohistochemistry in oropharyngeal squamous cell carcinoma and high-risk human papillomavirus RNA status. PMID:28621317
CDKN2A/B locus SNPs may impact type 2 diabetes risk by modulating islet gene expression and beta-cell proliferation. PMID:29432124
miR663 is upregulated in the serum of patients with NPC and NPC cells, and may promote the proliferation and cell cycle progression of NPC cells, at least in part through direct targeting of CDKN2A. PMID:28765905
Studied CDKN2A/B gene variants and association with increased risk of breast cancer; results show a correlation between the genetic polymorphism, rs10811661, in CDKN2A/B gene and breast cancer. PMID:28276595
p16 inhibits tenogenic differentiation of tendon stem/progenitor cells via microRNA signaling pathways. PMID:29036495
Oncogenic signaling induces ARF, and ARF further promotes p53 activation to inhibit proliferation. PMID:28484034
Data show that p16(INK4a) mRNA expression level was significantly negatively associated with handgrip strength in men but not in women. PMID:27549351
Significant immunoreactivity for p16(INK4a) was present in about one-fifth of the samples and figured as a surrogate marker of high-risk human papillomavirus infection in squamous cell carcinoma of the nasal vestibule. PMID:28371015
The p16-/HPV L1- pattern was significantly associated with the regression of CIN1. Moving from cervical intraepithelial neoplasia 1 (CIN1) to CIN2+ over time, p16+/HPV L1+ decreased, and p16+/HPV L1- increased. PMID:28277314